Microbiology Section, Department of Experimental Medicine, University of Perugia, Perugia, Italy.
Nat Protoc. 2010 Dec;5(12):1932-44. doi: 10.1038/nprot.2010.161. Epub 2010 Nov 10.
The mouse monoclonal antibody (mAb) technology still represents a key source of reagents for research and clinical diagnosis, although it is relatively inefficient and expensive and therefore unsuitable for high-throughput production against a vast repertoire of antigens. In this article, we describe a protocol that combines the immunization of individual mice with complex mixtures of influenza virus strains and a microarray-based immunoassay procedure to perform a parallel screening against the viral antigens. The protocol involves testing the supernatants of somatic cell hybrids against a capture substratum containing an array of different antigens. For each fusion experiment, we carried out more than 25,000 antigen-antibody reactivity tests in less than a week, a throughput that is two orders of magnitude higher than that of traditional antibody detection assays such as enzyme-linked immunosorbent assays and immunofluorescence. Using a limited number of mice, we can develop a vast repertoire of mAbs directed against nuclear and surface proteins of several human and avian influenza virus strains.
小鼠单克隆抗体 (mAb) 技术仍然是研究和临床诊断试剂的主要来源,尽管它相对效率低且昂贵,因此不适合针对大量抗原进行高通量生产。在本文中,我们描述了一种将个体小鼠免疫与流感病毒株的复杂混合物相结合的方案,并结合基于微阵列的免疫测定程序对病毒抗原进行平行筛选。该方案涉及测试体细胞杂交物的上清液与包含不同抗原阵列的捕获基质的反应。对于每个融合实验,我们在不到一周的时间内进行了超过 25,000 次抗原-抗体反应性测试,这一通量比传统的抗体检测方法(如酶联免疫吸附测定和免疫荧光)高出两个数量级。使用少量的小鼠,我们可以开发针对几种人类和禽流感病毒株的核蛋白和表面蛋白的大量 mAb。